PCI Pharma Services

What PCI Pharma Services does

PCI Pharma Services is a global Contract Development and Manufacturing Organization (CDMO) headquartered in Philadelphia, Pennsylvania, providing integrated pharmaceutical development, manufacturing, and packaging services to pharmaceutical manufacturers and biotechnology companies across the product lifecycle from clinical stages through commercial launch. The company's core offerings span two service categories: Sterile Services (sterile fill-finish, lyophilization, prefilled syringe filling, drug-device combination products including autoinjector assembly, and sterile clinical trial services) and Non-Sterile Services (high-potent drug development and manufacturing, oral targeted therapies, clinical and commercial packaging). Proprietary platforms include clinicalSMART™ for clinical supply project management, pci | bridge™ for digital supply chain management, Activ-Blister™ Solutions for compliance packaging, and SpeedSolutions™ for accelerated development. The company operates 38 GMP facilities across North America, Europe, and APAC with over 8,000 employees, and has invested over $1 billion in recent infrastructure expansions including a $100 million high-speed isolator filling line in San Diego, a GMP-ready vial and lyophilization line in Bedford, New Hampshire producing up to 33 million vials annually, and a $311 million Rockford, Illinois drug-delivery device plant expansion.

The company's business model is B2B contract services: revenue is generated through custom service contracts with pharmaceutical and biotechnology enterprises covering drug development, clinical supply packaging, temperature-controlled logistics, commercial serialization, and drug-device combination assembly. PCI serves two primary horizontal segments — pharmaceutical manufacturers requiring integrated solutions for next-generation biologics and injectable therapies, and biotechnology companies needing specialized sterile manufacturing capacity for novel therapeutics including mRNA and gene-editing treatments. Distribution is direct enterprise sales. The company is privately held and majority-backed by Bain Capital and Kohlberg following a July 2025 recapitalization at a $10 billion (including debt) valuation, with Mubadala and Partners Group as additional investors.

PCI has pursued an aggressive growth-by-acquisition and organic-capacity strategy, completing multiple acquisitions (Biotec Services International 2014, Penn Pharma 2014, Millmount Healthcare 2017, Sherpa Clinical Packaging 2018, Bellwyck Pharma Services 2020, LSNE 2021, Ajinomoto Althea 2025) and announcing concurrent multi-billion-dollar facility expansions, positioning it as a scaled US-based sterile manufacturing alternative for pharma clients prioritizing supply chain resilience.

Name

PCI Pharma Services

Legal name

PCI Pharma Services

Website

http://www.pciservices.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

PCI Pharma Services is a global CDMO providing integrated sterile and non-sterile pharmaceutical development, manufacturing, fill-finish, lyophilization, and drug-device combination services to pharmaceutical manufacturers and biotechnology companies across clinical and commercial stages, operating 38 GMP facilities with over 8,000 employees.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Development and Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412), Medical Equipment and Supplies Manufacturing (33911)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Packaging, Labeling & Serialization (Clinical/Commercial) CDMO (HLAGABAJ), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

Keywords

• Contract pharmaceutical manufacturing
• Sterile fill-finish services
• Lyophilization manufacturing
• Clinical trial packaging
• Drug-device combination products

Headquarters

HQ city

Philadelphia

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Manufacturing Services: CDMO services including sterile and non-sterile drug development, manufacturing, fill-finish, lyophilization, and drug-device combination products. Revenue is generated through service contracts with pharmaceutical and biotechnology companies across clinical and commercial stages.
2. Clinical Trial Services: Clinical supply packaging, temperature-controlled logistics, storage, distribution, and returns management for clinical trials
3. Commercial Packaging Technology: Commercial-stage pharmaceutical packaging including serialization, compliance packaging, and launch services

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

PCI Pharma Services is a global Contract Development and Manufacturing Organization (CDMO) that provides integrated pharmaceutical development, manufacturing, and packaging services to pharmaceutical and biotechnology companies. Its core offerings span sterile fill-finish, lyophilization, prefilled syringe filling, drug-device combination product assembly, high-potent drug development, clinical trial supply services, and commercial packaging technology across 38 global GMP facilities.

Product overview

PCI Pharma Services is a global Contract Development and Manufacturing Organization (CDMO) providing integrated pharmaceutical services across the entire product lifecycle. The company operates two primary service categories: Sterile Services (including sterile fill-finish, lyophilization, prefilled syringes, and drug-device combinations) and Non-Sterile Services (including high-potent drug development, oral targeted therapies, and commercial packaging). Key proprietary offerings include clinicalSMART™ for clinical supply project management, Activ-Blister™ Solutions for adherence packaging, SpeedSolutions™ for accelerated development, and pci | bridge™ for digital supply chain management. The portfolio spans development and manufacturing, clinical trial services, and commercial packaging technology, with specialized capabilities in biologics, advanced injectables, and temperature-sensitive products across 38 global GMP facilities.

Differentiator

Problem solved

Functional benefit

Products and services

• Sterile Fill-Finish & Lyophilization Sterile fill-finish services for vials and lyophilized products, including GMP-ready isolator vial and lyophilization lines capable of producing up to 33 million vials annually, for pharmaceutical and biotechnology clients.
• Prefilled Syringe Services Prefilled syringe filling services for ready-to-use prefilled syringes and cartridges, supported by high-speed isolator filling lines more than doubling existing capacity, targeting pharmaceutical manufacturers of injectable therapies.
• Advanced Drug Delivery & Drug-Device Combination Products Advanced drug delivery systems and drug-device combination products including autoinjector assembly infrastructure scaling to 250 million units annually, for pharmaceutical manufacturers of injectable therapeutics.
• Clinical Trial Services Sterile clinical trial services including advanced drug delivery systems, drug-device combination products, cold chain packaging and labeling, biologics packaging, compliance and adherence packaging, and storage, distribution and returns management for clinical trials.
• High-Potent Drug Development & Manufacturing High-potent drug development and manufacturing services including clinical and commercial manufacturing capabilities for potent compounds, serving pharmaceutical clients.
• Serialization & Anti-Counterfeiting Drug supply chain security and anti-counterfeiting solutions through serialization technology ensuring regulatory compliance for pharmaceutical products.
• Quality & Regulatory Services (QRS) Comprehensive quality and regulatory services supporting GMP compliance and regulatory submissions across global markets for pharmaceutical and biotech clients.
• Cold Chain Packaging & Labeling Temperature-controlled cold chain packaging and labeling services for temperature-sensitive pharmaceutical products including biologics, supporting both clinical and commercial supply.
• clinicalSMART™ Proprietary clinical supply project management platform that integrates with clinical trial services for efficient supply chain management and operational intelligence for clinical trial sponsors.
• Activ-Blister™ Solutions Proprietary activ-blister packaging solutions for clinical trials, enabling improved medication adherence and compliance packaging for clinical trial sponsors.
• pci | bridge™ Digital supply chain management platform providing digitally transformative CDMO services, enabling clients to manage and track their pharmaceutical supply chain operations.
• SpeedSolutions™ Accelerated solutions brand for rapid drug development and commercialization services, providing expedited timelines for pharmaceutical clients.

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• Ajinomoto Althea, Inc.coreStrategic or Co-development Partner · 1 May 2025PCI Pharma Services acquired Ajinomoto Althea in May 2025 to strengthen sterile manufacturing capabilities and expand advanced injectables production, including prefilled syringes and high-potency formats. The acquisition enhanced PCI's capacity for advanced injectable therapeutics.
• LSNE (Lyophilization Services of New England)coreStrategic or Co-development Partner · 12 October 2021PCI Pharma Services acquired LSNE, a contract development and manufacturing organization, to enhance global manufacturing capabilities including biologics and injectable therapies. The acquisition involved five FDA-approved facilities in the US and Europe, expanding PCI's global network and providing integrated drug development and manufacturing solutions.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Catalent: Leading global CDMO with deep capabilities in sterile fill-finish, prefilled syringes, biologics, and softgel/oral dose manufacturing. Most direct comparable to PCI in scale, service breadth, and customer base across pharma and biotech.
• Lonza Group: Swiss-based global CDMO leader offering biologics manufacturing, small molecule API, cell and gene therapy, and integrated drug substance/drug product services. Directly comparable in integrated CDMO model and biologics focus.
• Vetter Pharma: Specialist CDMO focused exclusively on aseptic fill-finish of prefilled syringes, vials, and cartridges. Closely comparable in sterile injectable capabilities and customer overlap with large pharma and biotech.
• Samsung Biologics: South Korea-based biologics CDMO providing mammalian cell culture, fill-finish, and aseptic manufacturing. Comparable as a global large-scale CDMO serving pharma clients with biologics and injectable therapeutics.
• WuXi STA (WuXi AppTec): China-based CDMO offering integrated API and drug product manufacturing including sterile fill-finish and injectable capabilities. Comparable in service breadth across small molecules and biologics for global pharma clients.
• Almac Group: Northern Ireland-based CDMO providing pharmaceutical development, commercial manufacturing, and clinical packaging services. Comparable in integrated service model and focus on complex pharma products.
• Recipharm: European CDMO specializing in sterile fill-finish, inhalation, and oral solid dose manufacturing. Comparable as a mid-sized global CDMO serving pharma clients across multiple dosage forms.
• Aenova Group: Germany-based CDMO offering solid, semi-solid, and sterile liquid manufacturing plus packaging. Comparable in scope of pharmaceutical manufacturing services and enterprise pharma customer base.

Broad incumbents

• Thermo Fisher Scientific (Patheon): Operates a global CDMO network (formerly Patheon) under its pharma services segment, offering drug substance, drug product, and clinical/commercial packaging. Broader portfolio than PCI but overlapping heavily in sterile and oral dose manufacturing.

Emerging players

• Grifols Pharmaceutical Manufacturing: Operates sterile fill-finish and contract manufacturing operations as part of broader plasma-derived therapies business. Partial overlap with PCI in sterile injectable manufacturing and biologics capabilities.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/PCI_Social
• LinkedInlinkedin.com/company/andersonbrecon

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries2 records

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PCI Pharma Services